Mitochondria: Prospective targets for neuroprotection in Parkinson’s disease

Current Pharmaceutical Design

Volumn 20, Issue 35, 2014, Pages 5558-5573

  Yadav, Anuradha ^a,b   Agarwal, Swati ^a,b   Tiwari, Shashi Kant ^a,b   Chaturvedi, Rajnish K ^a,b  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^b ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

Author keywords

Bioenergetic defects; Coenzyme Q10; Creatine; Mitochondrial dysfunction; Neurodegenerative diseases; Parkinson s disease; PGC 1 ; Sirtuins; Triterpenoids

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 HYDROXYBUTYRIC ACID; ALPHA SYNUCLEIN; ANTIOXIDANT; CARNITINE; CREATINE; DJ 1 PROTEIN; ENZYME; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LEUCINE RICH REPEAT KINASE 2; MANEB; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL TRANSCRIPTION FACTOR A; NEUROTOXIN; PARAQUAT; PARKIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE INDUCED KINASE 1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RESVERATROL; ROTENONE; SIRTUIN 2; SS PEPTIDE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIPARKINSON AGENT; NEUROPROTECTIVE AGENT; TRITERPENE;

ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; BIOENERGY; DOPAMINERGIC NERVE CELL; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HUMAN; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MITOPHAGY; MULTICENTER STUDY (TOPIC); NERVE DEGENERATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY CHAIN; SIGNAL TRANSDUCTION; UBIQUITINATION; UNIFIED PARKINSON DISEASE RATING SCALE; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PROCEDURES;

ANIMALS; ANTIPARKINSON AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MITOCHONDRIA; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; TRITERPENES;

EID: 84925882442     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140305224545     Document Type: Article

References (222)

1. [1] Murphy MP. How mitochondria produce reactive oxygen species. Biochem J 2009; 417: 1-13.
2. [2] Stadtman ER. Protein oxidation and aging. Free Radic Res 2006; 40: 1250-8.
3. [3] Dickinson BC, Chang CJ. Chemistry and biology of reactive oxygen species in signaling or stress responses. Nat Chem Biol 2011; 7: 504-11.
4. [4] Wei YH. Oxidative stress and mitochondrial DNA mutations in human aging. Proc Soc Exp Biol Med 1998; 217: 53-63.
5. [5] Arduino DM, Esteves AR, Cortes L, et al. Mitochondrial metabolism in Parkinson's disease impairs quality control autophagy by hampering microtubule-dependent traffic. Hum Mol Genet 2012; 21: 4680-702.
6. [6] Chaturvedi RK, Beal MF. Mitochondrial Diseases of the Brain. Free Radic Biol Med 2013; 63C: 1-29.
7. [7] Chaturvedi RK, Beal MF. Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases. Mol Cell Neurosci 2013; 55: 101-14.
8. [8] Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989; 1: 1269.
9. [9] Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990; 54: 823-7.
10. [10] Sherer TB, Betarbet R, Testa CM, et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 2003; 23: 10756-64.
11. [11] Coulom H, Birman S. Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster. J Neurosci 2004; 24: 10993-8.
12. [12] Gash DM, Rutland K, Hudson NL, et al. Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity. Ann Neurol 2008; 63:184-92.
13. [13] Betarbet R, Sherer TB, Mackenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000; 3: 1301-6.
14. [14] Sherer TB, Richardson JR, Testa CM, et al. Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J Neurochem 2007; 100: 1469-79.
15. [15] Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004; 5: 863-73.
16. [16] Loeffler DA, Demaggio AJ, Juneau PL, Havaich M, Lewitt PA. Levodopa administration to normal rats: influence on striatal oxidized glutathione concentration. Ann N Y Acad Sci 1994; 738: 421-6.
17. [17] Zigmond MJ, HastingsTG, Perez RG. Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity? Parkinsonism Relat Disord 2002; 8: 389-93.
18. [18] Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990; 39: 151-70.
19. [19] Perier C, Bove J, Dehay B, et al. Apoptosis-inducing factor deficiency sensitizes dopaminergic neurons to parkinsonian neurotoxins. Ann Neurol 2010; 68: 184-92.
20. [20] Castello PR, Drechsel DA, Patel M. Mitochondria are a major source of paraquat-induced reactive oxygen species production in the brain. J Biol Chem 2007; 282: 14186-93.
21. [21] Panov A, Dikalov S, Shalbuyeva N, Taylor G, Sherer T, Greenamyre JT. Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J Biol Chem 2005; 280: 42026-35.
22. [22] Gibson GE, Kingsbury AE, Xu H, et al. Deficits in a tricarboxylic acid cycle enzyme in brains from patients with Parkinson's disease. Neurochem Int 2003; 43: 129-35.
23. [23] Mizuno Y, Matuda S, Yoshino H, Mori H, Hattori N, Ikebe S. An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann Neurol 1994; 35: 204-10.
24. [24] She H, Yang Q, Shepherd K, et al. Direct regulation of complex I by mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and in human patients. J Clin Invest 2011; 121: 930-40.
25. [25] Swerdlow RH, Parks JK, Cassarino DS, et al. Biochemical analysis of cybrids expressing mitochondrial DNA from Contursi kindred Parkinson's subjects. Exp Neurol 2001; 169: 479-85.
26. [26] Gu M, Cooper JM, Taanman JW Schapira AH. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol 1998; 44: 177-86.
27. [27] Swerdlow RH, Parks JK, Miller SW, et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996; 40: 663-71.
28. [28] Swerdlow RH, Parks JK, Cassarino DS, et al. Characterization of cybrid cell lines containing mtDNA from Huntington's disease patients. Biochem Biophys Res Commun1999; 261: 701-4.
29. [29] Keeney PM, Dunham LD, Quigley CK, Morton SL, Bergguist KE, Bennett JP Jr. Cybrid models of Parkinson's disease show variable mitochondrial biogenesis and genotype-respiration relationships. Exp Neurol 2009; 220: 374-82.
30. [30] Keeney PM, Quigley CK, Dunham LD, et al. Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model. Hum Gene Ther 2009; 20: 897-907.
31. [31] Orsucci D, Caldarazzo Ienco E, Mancuso M, Siciliano G. POLG1-related and other mitochondrial parkinsonism: an overview. J Mol Neurosci, 2011; 44, 17-24.
32. [32] Mancuso M, Filosto M, Orsucci D, Siciliano G, et al. Mitochondrial DNA sequence variation and neurodegeneration. Hum Genomics 2008; 3: 71-8.
33. [33] Simon DK, Lin MT, Zheng L, et al. Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease. Neurobiol Aging 2004; 25: 71-81.
34. [34] Gu G, Reyes PE, Golden GT, et al. Mitochondrial DNA deletions/ rearrangements in parkinson disease and related neurodegenerative disorders. J Neuropathol Exp Neurol 2002; 61: 634-9.
35. [35] Ikebe S, Tanaka M, Ozawa T. Point mutations of mitochondrial genome in parkinson’s disease. Brain Res Mol Brain Res 1995; 28, 281-95.
36. [36] Lin MT, Cantuti-Castelvetri I, Zheng K, et al. Somatic mitochondrial DNA mutations in early parkinson and incidental lewy body disease. Ann Neurol 2012; 71: 850-4.
37. [37] Nishioka K, Vilarino-Guell C, Cobb SA, et al. Genetic variation of the mitochondrial complex I subunit NDUFV2 and Parkinson's disease. Parkinsonism Relat Disord 2010; 16: 686-7.
38. [38] Parker WD, Jr, Parks JK. Mitochondrial ND5 mutations in idiopathic Parkinson's disease. Biochem Biophys Res Commun 2005; 326: 667-9.
39. [39] Smigrodzki R, Parks J, Parker WD. High frequency of mitochondrial complex I mutations in Parkinson's disease and aging. Neurobiol Aging 2004; 25: 1273-81.
40. [40] Siciliano G, Mancuso M, Ceravolo R, Lombardi V, Iudice A, Bonuccelli U. Mitochondrial DNA rearrangements in young onset parkinsonism: two case reports. J Neurol Neurosurg Psychiatry 2001; 71: 685-7.
41. [41] Bender A, Krishnan KJ, Morris CM, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006; 38: 515-7.
42. [42] Kraytsberg Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW, Khrapko K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet 2006; 38: 518-20.
43. [43] Bender A, Schwarzkopf RM, McMillan A, et al. Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions. J Neurol 2008; 255: 1231-5.
44. [44] Luoma PT, Eerola J, Ahola S, et al. Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease. Neurology 2007; 69: 1152-9.
45. [45] Davidzon G, Greene P, Mancuso M, et al. Early-onset familial parkinsonism due to POLG mutations. Ann Neurol 2006; 59: 859-62.
46. [46] Tiangyou W, Hudson G, Ghezzi D, et al. POLG1 in idiopathic Parkinson disease. Neurology 2006; 67: 1698-700.
47. [47] Simon DK, Pulst SM, Sutton JP, Browne SE, Beal MF, Johns DR. Familial multisystem degeneration with parkinsonism associated with the 11778 mitochondrial DNA mutation. Neurology 1999; 53: 1787-93.
48. [48] Liang CL, Wang TT, Luby-Phelps K, German DC. Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease. Exp Neurol 2007; 203: 370-80.
49. [49] Burbulla LF, Schelling C, Kato H, et al. Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: functional impact of disease-related variants on mitochondrial homeostasis. Hum Mol Genet 2010; 19: 4437-52.
50. [50] De Mena L, Coto E, Sanchez-Ferrero E, et al. Mutational screening of the mortalin gene (HSPA9) in Parkinson's disease. J Neural Transm 2009; 116: 1289-93.
51. [51] Ekstrand MI, Terzioglu M, Galter D, et al. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci USA 2007; 104: 1325-30.
52. [52] Thomas B, Beal MF. Parkinson's disease. Hum Mol Genet 2007;16 Spec No. 2: R183-94.
53. [53] Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889-909.
54. [54] Kwong JQ, Beal MF, Manfredi G. The role of mitochondria in inherited neurodegenerative diseases. J Neurochem 2006; 97(6): 1659-75.
55. [55] Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443: 787-95.
56. [56] Lees AJ, Hardy J, Revesz T. "Parkinson's disease." Lancet 2009; 373: 2055-66.
57. [57] Abou-Sleiman PM, Muqit, MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 2006; 7: 207-19.
58. [58] Bonifati V, Rizzu P, Van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256-9.
59. [59] Irrcher I, Aleyasin H, Seifert EL, et al. Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum Mol Genet 2010; 19: 3734-46.
60. [60] Lavara-Culebras E, Paricio N. Drosophila DJ-1 mutants are sensitive to oxidative stress and show reduced lifespan and motor deficits. Gene 2007; 400: 158-65.
61. [61] Kim RH, Smith PD, Aleyasin H, et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci USA 2005; 102: 5215-20.
62. [62] Yang W, Chen L, Ding Y, Zhuang X, Kang UJ. Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice. Hum Mol Genet 2007; 16: 2900-10.
63. [63] Aleyasin H, Rousseaux MW, Marcogliese PC, et al. DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathway. Proc Natl Acad Sci USA 2010;107: 3186-91.
64. [64] Clements CM, McNally RS, Conti BJ, Mark TW, Ting JP. DJ-1, a cancer-and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci USA 2006; 103: 15091-6.
65. [65] Krebiehl G, Ruckerbauer S, Burbulla LF, et al. Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1. PLoS One 2010; 5: e9367.
66. [66] Ahn TB, Kim SY, Kim JY, et al. Alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology 2008; 70: 43-9.
67. [67] Ikeuchi T, Kakita A, Shiga A, et al. Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. Arch Neurol 2008; 65: 514-9.
68. [68] Ross OA, Braithwaite AT, Skipper LM, et al. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol 2008; 63: 743-50.
69. [69] Shavali S, Brown-Borg HM, Ebadi M, Porter J. Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells. Neurosci Lett 2008; 439: 125-8.
70. [70] Chinta SJ, Mallajosyula JK, Rane A, Andersen JK. Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett 2010; 486: 235-9.
71. [71] Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 2008; 283: 9089-100.
72. [72] Parihar MS, Parihar A, Fujita M, Hashimota M, Ghafourifar P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci 2008; 65: 1272-84.
73. [73] Nakamura K, Nemani VM, Azarbal F, et al. Direct membrane association drives mitochondrial fission by the Parkinson diseaseassociated protein alpha-synuclein. J Biol Chem 2011; 286: 20710-26.
74. [74] Hsu LJ, Sagara Y, Arroyo A, et al. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000; 157: 401-10.
75. [75] Song DD, Shults CW, Sisk A, Rockenstein E, Masliah E. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp Neurol 2004; 186: 158-72.
76. [76] Choubey V, Safiulina D, Vaarmann A, et al. Mutant A53T alphasynuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem 2011; 286: 10814-24.
77. [77] Dauer W, Kholodilov N, Vila M, et al. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA 2002; 99: 14524-9.
78. [78] Klivenyi P, Siwek D, Gardian G, et al. Mice lacking alphasynuclein are resistant to mitochondrial toxins. Neurobiol Dis 2006; 21: 541-8.
79. [79] Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang, AE. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 2007; 6: 652-62.
80. [80] Banerjee R, Starkov AA, Beal MF, ThomasB. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta 2009; 1792: 651-63.
81. [81] Kim SY, Seong MW, Jeon BS, et al. Phase analysis identifies compound heterozygous deletions of the PARK2 gene in patients with early-onset Parkinson disease. Clin Genet 2012; 82: 77-82.
82. [82] West AB, Maraganore D, Crook J, et al. Functional association of the parkin gene promoter with idiopathic Parkinson's disease. Hum Mol Genet 2002; 11: 2787-92.
83. [83] Stichel CC, Augustin M, Kuhn K, et al. Parkin expression in the adult mouse brain. Eur J Neurosci 2000; 12: 4181-94.
84. [84] Lu XH, Fleming SM, Meurers B, et al. Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alphasynuclein. J Neurosci 2009; 29: 1962-76.
85. [85] Palacino JJ, Sagi D, Goldberg MS, et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004; 279: 18614-22.
86. [86] Casarejos MJ, Menendez J, Solano RM, Rodriguez-Navarro JA, Garcia de Yebenes J, Mena MA. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J Neurochem 2006; 97: 934-46.
87. [87] Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin-induced mitophagy in the pathogenesis of Parkinson disease. Autophagy 2009; 5: 706-8.
88. [88] Muftuoglu M, Elibol B, Dalmizrak O, et al. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov Disord 2004;19: 544-8.
89. [89] Lee JY, Nagano Y, Taylor JP, Lim KL, Yao TP. Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy. J Cell Biol 2010; 189: 671-9.
90. [90] Valente, EM, Abou-Sleiman PM, Caputo V, et al. Hereditary earlyonset Parkinson's disease caused by mutations in PINK1. Science 2004; 304: 1158-60.
91. [91] Tan EK. PINK1 mutations and differential effects on mitochondrial function. Exp Neurol 2010; 221: 10-2.
92. [92] Gispert S, Ricciardi F, Kurz A, et al. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One 2009; 4: e5777.
93. [93] Gandhi S, Muqit MM, Stanyer L, et al. PINK1 protein in normal human brain and Parkinson's disease. Brain 2006; 129: 1720-31.
94. [94] Silvestri L, Caputo V, Bellacchio E, et al. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 2005; 14: 3477-92.
95. [95] Pridgeon JW, Olzmann JA, Chin LS. Li L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol 2007; 5: e172.
96. [96] Liu W, Vives-Bauza C, Acin-Perez R, et al. PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease. PLoS One 2009; 4: e4597.
97. [97] Abahuni N, Gispert S, Bauer P, et al. Mitochondrial translation initiation factor 3 gene polymorphism associated with Parkinson's disease. Neurosci Lett 2007; 414: 126-9.
98. [98] Wang HL, Chou AH, Wu AS, et al. PARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons. Biochim Biophys Acta 2011; 1812: 674-84.
99. [99] Wang HL, Chou AH, Yeh TH, et al. PINK1 mutants associated with recessive Parkinson's disease are defective in inhibiting mitochondrial release of cytochrome c. Neurobiol Dis 2007; 28: 216-26.
100. [100] Marongiu R, Spencer B, Crews L, et al. Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson's disease by disturbing calcium flux. J Neurochem 2009; 108: 1561-74.
101. [101] Haque ME, Thomas KJ, D'Souza C, et al. Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. Proc Natl Acad Sci USA, 2008; 105: 1716-21.
102. [102] Clark IE, Dodson MW, Jiang C, et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature, 2006; 441: 1162-6.
103. [103] Park J, Lee SB, Lee S, et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature, 2006; 441: 1157-61.
104. [104] Gautier CA, Kitada T, Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress, Proc Natl Acad Sci USA, 2008; 105: 11364-9.
105. [105] Strauss KM, Martins LM, Plun-Favreau H, et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet, 2005; 14: 2099-111.
106. [106] Bogaerts V, Nuytemans K, Reumers J, et al. Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson disease Hum Mutat, 2008; 29: 832-40
107. [107] Martins LM, Morrison A, Klupsch K, et al. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol, 2004; 24: 9848-62.
108. [108] Kieper N, Holmstrom KM, Ciceri D, et al. Modulation of mitochondrial function and morphology by interaction of Omi/HtrA2 with the mitochondrial fusion factor OPA1. Exp Cell Res, 2010; 316: 1213-24.
109. [109] Deng H, Dodson MW, Huang H, Guo M. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc Natl Acad Sci USA, 2008, 105, 14503-8.
110. [110] Yang Y, Ouyang Y, Yang L et al. Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc Natl Acad Sci USA, 2008; 105: 7070-5.
111. [111] Li C, Beal MF. Leucine-rich repeat kinase 2: a new player with a familiar theme for Parkinson's disease pathogenesis. Proc Natl Acad Sci USA, 2005, 102, 16535-6.
112. [112] Li Y, Liu W, Oo TF, et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci, 2009; 12: 826-8.
113. [113] Liu Z, Wang X, Yu Y, et al. A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci USA, 2008; 105: 2693-8.
114. [114] Cookson M R The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci, 2010; 11: 791-7.
115. [115] Mortiboys H, Johansen KK, Aasly JO, Bandmann O. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology, 2010; 75: 2017-20.
116. [116] Nguyen HN, Byers B, Cord B, et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell, 2011; 8: 267-80.
117. [117] Saha S, Guillily MD, Ferree A, et al. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci, 2009; 29: 9210-8.
118. [118] Van Laar VS, Berman SB. The interplay of neuronal mitochondrial dynamics and bioenergetics: Implications for Parkinson's disease. 2013; 51:43-55
119. [119] Santos D, Cardoso SM. Mitochondrial dynamics and neuronal fate in Parkinson's disease. Mitochondrion, 2012; 12: 428-437.
120. [120] Chaturvedi RK, Beal MF. Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases. Mol Cell Neurosci, 2013; 55:101-14
121. [121] Niu J, Yu M, Wang C, Xu Z. Leucine-Rich Repeat Kinase 2 (LRRK2) Disturbs Mitochondrial Dynamics via Dynamin-Like Protein (DLP1). J Neurochem, 2012;122:650-8.
122. [122] Xie W, Chung K K. Alpha-synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson's disease. J Neurochem, 2012;122:404-14.
123. [123] Wang X, Yan MH, Fujioka H, et al. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet, 2012; 21: 1931-44.
124. [124] Wang X, Petrie TG, Liu Y, Liu J, Fujioka H, Zhu X. Parkinson's disease-associated DJ-1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction. J Neurochem, 2012; 121: 830-839.
125. [125] Liu S, Sawada T, Lee S, et al. Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria. PLoS Genet, 2012; 8, e1002537.
126. [126] Wang X, Petrie TG, Liu Y, Liu J, Fujioka H, Zhu X. Parkinson's disease-associated DJ-1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction. J Neurochem, 2012; 121: 830-9.
127. [127] Yu W, Sun Y, Guo S, Lu B. The PINK1/Parkin pathway regulates mitochondrial dynamics and function in mammalian hippocampal and dopaminergic neurons. Hum Mol Genet, 2011; 20: 3227-40.
128. [128] Narendra, D. P.; Jin, S. M.; Tanaka, A.; Suen, D. F.; Gautier, C. A.; Shen, J.; Cookson, M. R.; Youle, R. J. "PINK1 is selectively stabilized on impaired mitochondria to activate Parkin." PLoS Biol, 2010, 8, e1000298.
129. [129] Ziviani E, Tao RN, Whitworth AJ. Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin. Proc Natl Acad Sci USA, 2010; 107: 5018-23.
130. [130] Gegg ME, Cooper JM, Chau KY, Rojo M, Schapira AH, Taanman JW. Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Hum Mol Genet, 2010; 19: 4861-70.
131. [131] Geisler S, Holmstrom KM, Skujat D et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol, 2010; 12: 119-31.
132. [132] Narendra D, Kane LA, Hauser DN, Fearnley IM, Youle RJ. p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both. Autophagy, 2010; 6: 1090-106.
133. [133] Sun Y, Vashisht AA, Tchieu J, Wohlschlegel JA, Dreier L. Voltage-dependent anion channels (VDACs) recruit Parkin to defective mitochondria to promote mitochondrial autophagy. J Biol Chem, 2012; 287: 40652-60.
134. [134] Wang X, Winter D, Ashrafi G, et al. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell, 2011; 147: 893-906.
135. [135] Narendra DP, Youle RJ. Neurodegeneration: Trouble in the cell's powerhouse. Nature, 2012; 483: 418-9.
136. [136] Narendra DP, Youle RJ. Targeting mitochondrial dysfunction: role for PINK1 and Parkin in mitochondrial quality control. Antioxid Redox Signal, 2011; 14: 1929-38.
137. [137] Chaturvedi RK, Beal MF. Mitochondrial approaches for neuroprotection." Ann N Y Acad Sci, 2008; 1147: 395-412.
138. [138] Matthews RT, Ferrante RJ, Klivenyi P, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol, 1999; 157: 142-9.
139. [139] Klivenyi P, Gardian G, Calingasan NY, Yang L, Beal MF. Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J Mol Neurosci, 2003; 21: 191-8.
140. [140] Yang L, Calingasan NY, Wille EJ, et al. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem, 2009; 109: 1427-39.
141. [141] Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, Tarnopolsky MA. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve, 2007; 35: 235-42.
142. [142] Bender A, Koch W, Elstner M, et al. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology, 2006; 67: 1262-4.
143. [143] Bender, A, Samtleben W, Elstner M, Klopstock T. Long-term creatine supplementation is safe in aged patients with Parkinson disease. Nutr Res, 2008; 28: 172-8.
144. [144] Hass CJ, Collins MA, Juncos JL. Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: a randomized trial." Neurorehabil Neural Repair, 2007; 21: 107-15.
145. [145] NINDS NET-PD, A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology, 2006; 66: 664-7.
146. [146] Investigators NP. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol, 2008; 31: 141-50.
147. [147] Couzin J. Clinical research. Testing a novel strategy against Parkinson's disease. Science, 2007; 315: 1778.
148. [148] Beal MF. Neuroprotective effects of creatine. Amino Acids, 2011; 40: 1305-13.
149. [149] Beal MF. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann Neurol, 2003; 53 Suppl 3, S39-47.
150. [150] Schulz, JB, Henshaw DR, Matthews RT, Beal MF. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp Neurol, 1995; 132: 279-83.
151. [151] Beal MF, Matthews RT, Tieleman A, Shults CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res, 1998; 783: 109-14.
152. [152] Cleren C, Yang L, Lorenzo B, et al. Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J Neurochem, 2008; 104: 1613-21.
153. [153] Somayajulu-Nitu M, Sandhu J K, Cohen J, et al. Paraquat induces oxidative stress, neuronal loss in substantia nigra region and parkinsonism in adult rats: neuroprotection and amelioration of symptoms by water-soluble formulation of coenzyme Q10. BMC Neurosci, 2009; 10: 88.
154. [154] Bergamini C, Moruzzi N, Sblendido A, Lenaz G, Fato R. A water soluble CoQ10 formulation improves intracellular distribution and promotes mitochondrial respiration in cultured cells. PLoS One, 2012; 7: e33712.
155. [155] Naderi J, Somayajulu-Nitu M, Mukerji A. et al. Water-soluble formulation of Coenzyme Q10 inhibits Bax-induced destabilization of mitochondria in mammalian cells. Apoptosis, 2006; 11: 1359-69.
156. [156] Spindler M, Beal M F, Henchcliffe C. Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat, 2009; 5: 597-610.
157. [157] Shults CW, Beal MF, Fontaine D, Nakano K, Haas RH. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology, 1998; 50:793-5.
158. [158] Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol, 2002; 59: 1541-50.
159. [159] Muller T, Buttner T, Gholipour AF, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett, 2003; 341: 201-4.
160. [160] Horstink MW, van Engelen BG. The effect of coenzyme Q10 therapy in Parkinson disease could be symptomatic. Arch Neurol, 2003; 60: 1170-2.
161. [161] Storch A, Nervenarzt. Coenzyme Q10 in Parkinson's disease. Symptomatic or neuroprotective effects? 2007; 78: 1378-82.
162. [162] Storch A, Jost WH, Vieregge P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol, 2007; 64: 938-44.
163. [163] Shults CW, Beal MF, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol, 2004; 188: 491-4.
164. [164] NINDS-NETPD. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology, 2007; 68: 20-8.
165. [165] Armstrong JS. Mitochondria-Directed Therapeutics. Antioxid Redox Signal, 2008; 10:575-8.
166. [166] Manczak M, Mao P, Calkins MJ, et al. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J Alzheimers Dis, 2010; 20: S609-31.
167. [167] Adlam VJ, Harrison JC, Porteous CM, et al. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. Faseb J, 2005; 19: 1088-95.
168. [168] Solesio ME, Prime TA, Logan A, et al. The mitochondria-targeted anti-oxidant MitoQ reduces aspects of mitochondrial fission in the 6-OHDA cell model of Parkinson's disease. Biochim Biophys Acta, 2013; 1832: 174-82.
169. [169] Ghosh A, Chandran K, Kalivendi SV, et al. Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model. Free Radic Biol Med, 2010; 49: 1674-84.
170. [170] Snow BJ, Rolfe FL, Lockhart MM, et al. A double-blind, placebocontrolled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord, 2010; 25: 1670-4.
171. [171] Szeto HH. Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury. Antioxid Redox Signal, 2008; 10: 601-19.
172. [172] Zhao K, Zhao GM, Wu, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem, 2004; 279: 34682-90.
173. [173] Petri S, Kiaei M, Damiano M, et al. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem, 2006; 98: 1141-8.
174. [174] McGill JK, Beal MF. PGC-1alpha, a new therapeutic target in Huntington's disease? Cell, 2006; 127: 465-8.
175. [175] Spiegelman BM, Heinrich R. Biological control through regulated transcriptional coactivators. Cell, 2004; 119: 157-67.
176. [176] Lin J, Wu H, Tarr PT, et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature, 2002; 418: 797-801.
177. [177] Uldry M, Yang W, St-Pierre J, Lin J, Seale P, Spiegelman BM. Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiation. Cell Metab, 2006; 3: 333-41.
178. [178] Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev, 2006; 27: 728-35.
179. [179] Spiegelman B M. Transcriptional control of mitochondrial energy metabolism through the PGC1 coactivators. Novartis Found Symp, 2007; 287: 60-3.
180. [180] Cu L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell, 2006; 127: 59-69.
181. [181] Weydt P, Pineda VV, Torrence AE, et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab, 2006; 4: 349-62.
182. [182] Chaturvedi RK, Adhihett P, Shukla S, et al. Impaired PGC-1alpha function in muscle in Huntington's disease. Hum Mol Genet, 2009; 18: 3048-65.
183. [183] Chaturvedi RK, Calingasan NY, Yang L, Hennessey T, Johri A, Beal MF. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. Hum Mol Genet, 2010; 19: 3190-205.
184. [184] Johri A, Starkov AA, Chandra, et al. Truncated peroxisome proliferator-activated receptor-gamma coactivator 1alpha splice variant is severely altered in Huntington's disease. Neurodegener Dis, 2011; 8: 496-503.
185. [185] Leone TC, Lehman JJ, Finck BN, et al. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol, 2005; 3: e101.
186. [186] Lin J, Wu PH, Tarr PT, et al. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell, 2004; 119: 121-35.
187. Zheng B, Liao Z, Locascio JJ, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med, 2010; 2: 52-73.
188. [188] St-Pierre J, Drori S, Uldry M, et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell, 2006; 127: 397-408.
189. [189] Mudo G, Makela J, Di Liberto V, et al. Transgenic expression and activation of PGC-1alpha protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cell Mol Life Sci, 2012; 69: 1153-65.
190. [190] Shin JH, Ko HS, Kang H, et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell, 2011; 144: 689-702.
191. [191] Ciron C, Lengacher S, Dusonchet J, Aebischer P, Schneider BL. Sustained expression of PGC-1alpha in the rat nigrostriatal system selectively impairs dopaminergic function. Hum Mol Genet, 2012; 21: 1861-76.
192. [192] Clark J, Reddy S, Zheng K, Betensky RA, Simon DK. Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson's disease. BMC Med Genet, 2011; 12: 69.
193. [193] Johri A, Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. J Pharmacol Exp Ther, 2012; 342: 619-30.
194. [194] Clark J, Simon DK. Transcribe to survive: transcriptional control of antioxidant defense programs for neuroprotection in Parkinson's disease. Antioxid Redox Signal, 2009; 11: 509-28.
195. [195] Chaturvedi RK, Hennessey T, Johri A, et al. Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease. Hum Mol Genet, 2012; 21: 3474-88.
196. [196] Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev, 1999; 20: 649-88.
197. [197] Straus DS, Glass CK. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev, 2001; 21: 185-210.
198. [198] Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med, 2002; 53: 409-35.
199. [199] Castrillo A, Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol, 2004; 20: 455-80.
200. [200] Nolte RT, Wisely GB, Westin S, et al. Ligand binding and coactivator assembly of the peroxisome proliferator-activated receptor-gamma. Nature, 1998; 395: 137-43.
201. [201] Chaturvedi RK, Beal MF. PPAR: a therapeutic target in Parkinson's disease. J Neurochem, 2008; 106: 506-18.
202. [202] Clark J, Silvaggi JM, Kiselak T, et al. Pgc-1alpha overexpression downregulates Pitx3 and increases susceptibility to MPTP toxicity associated with decreased Bdnf. PLoS One, 2012; 7: e48925.
203. [203] Zhang A, Wang H, Qin X, Pang S, Yan B. Genetic analysis of SIRT1 gene promoter in sporadic Parkinson's disease." Biochem Biophys Res Commun, 2012; 422: 693-6.
204. [204] Donmez G, Arun A, Chung CY, McLean PJ, Lindquist S, Guarente L. SIRT1 protects against alpha-synuclein aggregation by activating molecular chaperones. J Neurosci, 2012; 32: 124-32.
205. [205] Wu PF, Xie N, Zhang JJ, et al. Resveratrol preconditioning increases methionine sulfoxide reductases A expression and enhances resistance of human neuroblastoma cells to neurotoxins. J Nutr Biochem, 2013; 24: 1070-7.
206. [206] Wu Y, Li X, Zhu JX, et al. Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals, 2011; 19: 163-74.
207. [207] Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 2006; 127: 1109-22.
208. [208] Ye Q, Ye L, Xu X, et al. Epigallocatechin-3-gallate suppresses 1-methyl-4-phenyl-pyridine-induced oxidative stress in PC12 cells via the SIRT1/PGC-1alpha signaling pathway. BMC Complement Altern Med, 2012; 12: 82.
209. [209] Ng CH, Guan MS, Koh C, et al AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson's disease. J Neurosci, 2012; 32: 14311-7.
210. [210] Choi JS, Park C, Jeong JW. AMP-activated protein kinase is activated in Parkinson's disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochem Biophys Res Commun, 2010; 391: 147-51.
211. [211] Liby K, Hock T, Yore, et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res, 2005; 65: 4789-98.
212. [212] Yates MS, Tauchi M, Katsuoka F, et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther, 2007; 6: 154-62.
213. [213] Lee JM, Shih AY, Murphy TH, Johnson JA. NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J Biol Chem, 2003; 278: 37948-56.
214. [214] Yang L, Zhao K, Calingasan NY, Luo G, Szeto HH, Beal MF. Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Antioxid Redox Signal, 2009; 11: 2095-104.
215. [215] Kaidery NA, Banerjee R, Yang L, et al. Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. Antioxid Redox Signal, 2013; 18: 139-57.
216. [216] Yan L, Calingasan NY, Thomas B, et al. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS One, 2009; 4: e5757.
217. [217] Castro-Caldas M, Carvalho AN, Rodrigues E, et al. Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease. J. Mol Neurobiol, 2012; 46: 475-86.
218. [218] Singh M, Murthy V, Ramassamy C. Standardized extracts of Bacopa monniera protect against MPP+-and paraquat-induced toxicity by modulating mitochondrial activities, proteasomal functions, and redox pathways. Toxicol Sci, 2012; 125: 219-32.
219. [219] Zaitone SA, Abo-Elmatty DM, Shaalan AA. Acetyl-L-carnitine and alpha-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy. Pharmacol Biochem Behav, 2012; 100: 347-60.
220. [220] Abdin AA, Sarhan NI. Intervention of mitochondrial dysfunctionoxidative stress-dependent apoptosis as a possible neuroprotective mechanism of alpha-lipoic acid against rotenone-induced parkinsonism and L-dopa toxicity. Neurosci Res, 2011; 71: 387-95.
221. [221] Shim JH, Yoon SH, Kim KH, et al. The antioxidant Trolox helps recovery from the familial Parkinson's disease-specific mitochondrial deficits caused by PINK1-and DJ-1-deficiency in dopaminergic neuronal cells. Mitochondrion, 2011; 11: 707-15.
222. [222] Pan J, Li H, Ma JF, et al. Curcumin inhibition of JNKs prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease through suppressing mitochondria dysfunction. Transl Neurodegener, 2012; 1: 16.